Throughout our history, we’ve been creating brighter futures
Today, Stryker's Interventional Spine business is all in—providing an extensive and innovative product portfolio for vertebral augmentation, radiofrequency ablation, bone tumor ablation and minimally invasive lumbar decompression procedures.
2000
Our first vertebroplasty products are launched.
2004
Single lesion RF generator is introduced.
2008
MultiGen® radiofrequency generator with 4 lesion capability is launched.
2008
Our first automatic mixer, AutoPlex®, and VertaPlex® bone cement are launched.
2010
VertaPlex® HV PMMA bone cement is developed to address specific viscosity and working time preferences for treating vertebral compression fractures.
2010
Our first kyphoplasty device, 10-guage iVAS® balloon system, is launched.
2013
Venom® cannula and electrode system is launched, which delivers large lesions in a short amount of time.1,2
2013
11-gauge iVAS® balloon system, available in 10mm and 15mm balloon sizes, is launched.
2013
8-gauge iVAS® balloon system is launched.
2014
VertePort X4 Manifold® cement delivery assistant and TroFlex curved needle is launched.
2015
VertaPlex® HV bone cement becomes the first PMMA in the U.S. to receive 510(k) clearance for the fixation of pathological fractures of the sacral vertebral body or ala, using sacral vertebroplasty or sacroplasty.
2016
CareFusion's vertebral compression fracture (VCF) portfolio, including the AVAFlex® balloon system, is acquired by Stryker.
2017
AVAFlex® balloon system is launched for use with our bone cements and the AutoPlex® mixing and delivery system.
2017
MultiGen® 2 RF generator, made for reliability, efficiency and ultimate control and customization, launches.
2017
Vexim is acquired.
2018
iVAS® Elite high-pressure balloon system (rated to 808 psi) is launched.
2019
SAKOS pivotal trial results are released. This study demonstrated the non-inferiority of SpineJack® system to BKP and also established the superiority of SpineJack system over BKP with regards to reduced adjacent level fractures (ALFs) and restored midline vertebral body (VB) height at both 6 and 12 months after the procedure.3
2019
SpineJack® system receives 510(k) clearance in the U.S. for treatment of osteoporotic vertebral compression fractures.
2020
CMS grants new technology add-on payment (NTAP) for SpineJack® system, which provides eligible hospitals with incremental reimbursement for the SpineJack system for fiscal years 2021-2022 (October 1, 2020 to September 30, 2022).4,5
2021
CMS grants transitional pass-through payment for SpineJack® system, which provides eligible outpatient settings and ambulatory surgery centers (ASCs) with incremental add-on payment for SpineJack system treatment due to substantial clinical improvement demonstrated over existing technologies.6
2021
SpineJack® system receives 510(k) clearance in the U.S. for treatment of type A traumatic vertebral compression fractures with or without posterior instrumental fixation.
2022
OptaBlate® bone tumor ablation system received 510(k) clearance in the U.S. for treatment of painful benign and metastatic bone tumors.
2022
OmniCurve® unipedicular curved balloon system is released with enhancements to reach midline more reliably.7
2022
SpineJack® system receives 510(k) clearance for the fixation of compression fractures that result from malignant lesions – myeloma or osteolytic metastasis.
2024
Building on the gold standard you expect, the upgraded AutoPlex® M4 is adding control to the mix.
2024
Vertos Medical, Inc. is acquired by Stryker, including the mild® procedure.
2025
OptaBlate® Curve Probes receives 510(k) clearance for a unipedicular curved bone tumor ablation system.
2025
OptaBlate® BVN System receives 510(k) clearance from the U.S Food and Drug Administration for basivertebral nerve ablation.
Bolder approaches begin here
By continuously investing in research and technology, we provide advanced medical technology for interventional spine procedures. We aren’t settling with the current standard of care. We continually ask, “What if?” and “What’s next?”—because that’s where bolder approaches and improved outcomes begin.
Every day, we’re turning our vision into action
The vision of IVS is to improve the life of patients with advanced percutaneous solutions that help treat chronic pain and restore mobility. Minimally invasive procedures such as vertebral augmentation procedures and radiofrequency ablation may help provide pain relief.
A global leader by your side
Guided by feedback from our customers, we’re creating advanced percutaneous solutions. We don’t just want to be your provider. We want to be a partner that helps you drive procedural efficiencies, pursue improved outcomes and expand into new procedures.
Interested in learning more?
Contact us.
Pain is unrelenting. But so are we.
Thank you for your interest in Stryker's Interventional Spine products—bold and innovative approaches for treating patients experiencing pain. Tell us how we can help by answering the following questions, and we’ll work to get you what you need.
To place an order, contact your Stryker's Sales Representative or Stryker's Customer Service at 1 800 253 3210.
Thank you!
Be in the know
Engage with us LinkedIn and Instagram to find information about upcoming MedEd events, including webinars, and to be among the first to receive news on technology enhancements, new clinical data and more.
- Based on 18g Venom cannula and electrode system.
- Stryker Corporation. (2021). Effect of Venom cannula and electrode system on lesion size and anesthesia delivery during radiofrequency ablation. [Clinical white paper, D0000088252 Rev AA.1]. Portage, MI.
- Noriega D et al. A prospective, international, randomized, non-inferiority study comparing an implantable titanium vertebral augmentation device versus balloon kyphoplasty in the reduction of vertebral compression fractures (SAKOS study). The Spine Journal. 2019. doi: 10.1016/j.spinee.2019.07.009.
- FY 2021 Medicare Hospital Inpatient Prospective Payment System and Long Term Care Hospital Rates Final Rule (CMS-1735-F). Available from: https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-19637.pdf
- FY 2022 Medicare Hospital Inpatient Prospective Payment System and Long Term Care Hospital Rates Final Rule (CMS-1752-F). Available from: https://public-inspection.federalregister.gov/2021-16519.pdf
- CY 2021 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule (CMS-1736-FC). Available from: https://www.cms.gov/files/document/12220-opps-final-rule-cms-1736-fc.pdf
- Stryker data on file.
IVS-GSNPS-SYK-1983550_REV-0